Literature DB >> 23229183

Which way is forward in the treatment of rectal cancer?

Rob L H Jansen1, Geerard L Beets.   

Abstract

Preoperative 5-fluorouracil-based chemoradiation with optimal surgery provides very effective local control in locally advanced rectal cancer. Does adding oxaliplatin as a radiosensitizer provide any additional benefit? Is more always better?

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23229183     DOI： 10.1038/nrclinonc.2012.217

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


  8 in total

1.  Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer.

Authors:  Monique Maas; Regina G H Beets-Tan; Doenja M J Lambregts; Guido Lammering; Patty J Nelemans; Sanne M E Engelen; Ronald M van Dam; Rob L H Jansen; Meindert Sosef; Jeroen W A Leijtens; Karel W E Hulsewé; Jeroen Buijsen; Geerard L Beets
Journal:  J Clin Oncol       Date:  2011-11-07       Impact factor: 44.544

2.  Non-operative management of rectal cancer after neoadjuvant chemoradiation.

Authors:  A Habr-Gama; R O Perez
Journal:  Br J Surg       Date:  2009-02       Impact factor: 6.939

3.  Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial.

Authors:  Claus Rödel; Torsten Liersch; Heinz Becker; Rainer Fietkau; Werner Hohenberger; Torsten Hothorn; Ullrich Graeven; Dirk Arnold; Marga Lang-Welzenbach; Hans-Rudolf Raab; Heiko Sülberg; Christian Wittekind; Sergej Potapov; Ludger Staib; Clemens Hess; Karin Weigang-Köhler; Gerhard G Grabenbauer; Hans Hoffmanns; Fritz Lindemann; Anke Schlenska-Lange; Gunnar Folprecht; Rolf Sauer
Journal:  Lancet Oncol       Date:  2012-05-23       Impact factor: 41.316

4.  Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial.

Authors:  Carlo Aschele; Luca Cionini; Sara Lonardi; Carmine Pinto; Stefano Cordio; Gerardo Rosati; Salvatore Artale; Angiolo Tagliagambe; Giovanni Ambrosini; Paola Rosetti; Andrea Bonetti; Maria Emanuela Negru; Maria Chiara Tronconi; Gabriele Luppi; Giovanni Silvano; Domenico Cristiano Corsi; Anna Maria Bochicchio; Germana Chiaulon; Maurizio Gallo; Luca Boni
Journal:  J Clin Oncol       Date:  2011-05-23       Impact factor: 44.544

Review 5.  Targeted therapies: how personal should we go?

Authors:  Miriam Martini; Loredana Vecchione; Salvatore Siena; Sabine Tejpar; Alberto Bardelli
Journal:  Nat Rev Clin Oncol       Date:  2011-11-15       Impact factor: 66.675

6.  Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2.

Authors:  Jean-Pierre Gérard; David Azria; Sophie Gourgou-Bourgade; Isabelle Martel-Laffay; Christophe Hennequin; Pierre-Luc Etienne; Véronique Vendrely; Eric François; Guy de La Roche; Olivier Bouché; Xavier Mirabel; Bernard Denis; Laurent Mineur; Jean-François Berdah; Marc André Mahé; Yves Bécouarn; Olivier Dupuis; Gérard Lledo; Christine Montoto-Grillot; Thierry Conroy
Journal:  J Clin Oncol       Date:  2010-03-01       Impact factor: 44.544

Review 7.  Local staging of rectal cancer: a review of imaging.

Authors:  Regina G H Beets-Tan; Geerard L Beets
Journal:  J Magn Reson Imaging       Date:  2011-05       Impact factor: 4.813

8.  Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer.

Authors:  Jean-Pierre Gérard; David Azria; Sophie Gourgou-Bourgade; Isabelle Martel-Lafay; Christophe Hennequin; Pierre-Luc Etienne; Véronique Vendrely; Eric François; Guy de La Roche; Olivier Bouché; Xavier Mirabel; Bernard Denis; Laurent Mineur; Jean-François Berdah; Marc-André Mahé; Yves Bécouarn; Olivier Dupuis; Gérard Lledo; Jean-François Seitz; Laurent Bedenne; Béata Juzyna; Thierry Conroy
Journal:  J Clin Oncol       Date:  2012-10-29       Impact factor: 44.544
  8 in total
  1 in total

1.  Systematic review of treatment intensification using novel agents for chemoradiotherapy in rectal cancer.

Authors:  R Clifford; N Govindarajah; J L Parsons; S Gollins; N P West; D Vimalachandran
Journal:  Br J Surg       Date:  2018-11       Impact factor: 6.939
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.